

Online Dissolution Testing of Supplements

A. Tanabe, K. Matsuoka

User Benefits

- ◆ Dissolution testing can be automated.
- ◆ The automatic sampling function enables testing with good reproducibility.
- ◆ Dissolution testing of supplements is possible in the same manner as with pharmaceuticals.

Introduction

Dissolution testing is conducted for formulation development, quality control, bioequivalence tests of generic drugs, etc. In dissolution testing, the dissolution properties of a drug product are checked under specific conditions for certain periods. Dissolution testing takes a lot of labor and time, since dissolution media must be sampled from multiple vessels every sampling time and analyzed.

Nexera FV is an HPLC system for online dissolution testing.

It can automate the processes from sampling dissolution media, HPLC analysis, up to report output. By automating tasks that used to be conducted manually by operators, the system realizes labor saving and throughput improvement. In addition, automating tasks prevent human errors from whole processes.

This article introduces the workflow of online dissolution testing of two kinds of supplements using Nexera FV.

Nexera FV has two modes of analysis: direct injection mode to inject the dissolution media delivered from the dissolution tester directly to the HPLC, and fraction analysis mode to fractionate the dissolution media into vials and analyze them. The former is effective when an analysis is enough short to complete by the next sampling time. The latter is used in tests with short sampling intervals, and in cases where dilution or addition of internal standards is required.

Furthermore, the fraction analysis mode also makes it possible to conduct HPLC analyses between sampling intervals. As a result, the total time could be reduced by 30%.

Online Dissolution Testing with Nexera FV

Fig. 1 shows a comparative example of the workflow of conventional method and online dissolution testing with Nexera FV.

The Nexera FV system can automate sampling of dissolution medium at designated times, filtration, dilution, addition of internal standards, HPLC analysis, and report generation, processes which had been conducted manually. Furthermore, the HPLC analytical conditions can be set easily by the dedicated software of DT-Solution (Fig. 2), and a report summarizing multiple data such as the dissolution rate is prepared simultaneously with completion of the analysis (Fig. 3)




Fig. 2 DT-Solution Setting Window



Fig. 3 Multi Data Report^{*1} Window




Fig. 1 Comparison of Workflow of Online Dissolution Testing^{*2}

*1 Multi Data Report is an optional function of LabSolutions™DB/CS to generate reports automatically.

*2 The time above is an example of α-lipoic acid capsule with a dissolution test of 4 h and an HPLC analysis of 2.5 hours (50 analyses of 3 minutes each).

■ Dissolution Testing of Vitamin B2 (Riboflavin)

A dissolution test of riboflavin (labeled amount: 12 mg/tablet) was conducted using commercially-available vitamin B group tablets. Fig.4 shows the chromatogram of vitamin B group tablet at a dissolution time of 60 min. Table 1 and Table 2 show the dissolution conditions and the HPLC conditions, respectively. Table 3 shows the results of the reproducibility of the retention time and area for riboflavin when using a 10 mg/L standard solution, Table 4 shows the dissolution rate at each sampling time, and Fig. 5 shows the dissolution curve.




Fig. 4 Chromatogram of Vitamin B Group Tablet

Table 1 Dissolution Conditions (Riboflavin)

System	: NTR-6600AST (TOYAMA SANGYO CO., LTD.)
Dissolution method	: Paddle
Dissolution media	: Water
Media volume	: 900 mL
Rotation speed	: 100 rpm
Bath temperature	: 37 °C
Total time	: 90 min
Sampling time	: 5, 10, 15, 20, 30, 45 and 60 min


Table 2 HPLC Conditions (Riboflavin)

Column	: Shim-pack™ VP-ODS ^{*1} (150 mm × 4.6 mm I.D., 5 μm) 10 mmol/L (Sodium) phosphate buffer (pH2.6)
Mobile phase	: / acetonitrile = 80 : 20
Flow rate	: 1.0 mL/min
Column temp.	: 40 °C
Injection vol.	: 10 μL
Vial	: Shimadzu Vial, LC, 1.1 mL, Glass ^{*2}
Detection	: UV 210 nm

*1 P/N: 228-34937-91 *2 P/N: 228-21283-91

Table 3 Reproducibility of Retention Time and Area for Riboflavin (10 mg/L, n=6)

	Retention time (min)	Area
1 st	2.261	182371
2 nd	2.260	182342
3 rd	2.260	182192
4 th	2.260	182266
5 th	2.261	182251
6 th	2.262	182250
Average	2.261	182279
%RSD	0.0231	0.0364



* Dissolution rate (%) = Concentration (mg/L) × Media volume 0.9 (L) / Labeled amount 12 (mg) × 100

Fig. 5 Dissolution Curve of Riboflavin

Table 4 Dissolution Rate of Riboflavin (%)

Vessel No. \ Time (min)	5	10	15	20	30	45	60
1	15.2	33.4	50.8	72.2	99.5	106.1	107.7
2	15.1	34.0	52.5	73.0	100.8	106.9	108.7
3	14.3	31.3	49.7	69.2	100.0	106.9	108.4
4	15.8	33.4	54.0	74.0	101.1	106.9	108.0
5	14.6	32.0	50.6	70.8	99.6	106.3	108.0
6	15.3	32.9	50.9	72.7	101.1	107.0	108.2
Average	15.0	32.8	51.4	72.0	100.3	106.7	108.2
%RSD	3.2	2.8	2.7	2.2	0.7	0.3	0.3

■ Dissolution Testing of α -Lipoic Acid

A dissolution test of α -lipoic acid (labeled amount: 105 mg/capsule) was conducted using commercial α -lipoic acid capsules. A sinker was used in the dissolution process. Fig. 6 shows the chromatogram of α -lipoic acid capsule at a dissolution time of 240 min. Table 5 and Table 6 show the dissolution conditions and the HPLC conditions, respectively. Table 7 shows the results of the reproducibility of the retention time and area for α -lipoic acid when using a 100 mg/L standard solution, Table 8 shows the dissolution rate at each sampling time, and Fig. 7 shows the dissolution curve.




Fig. 6 Chromatogram of α -Lipoic Acid Capsule

Table 5 Dissolution Conditions (α -Lipoic Acid)

System	: NTR-6600AST (TOYAMA SANGYO CO., LTD.)
Dissolution method	: Paddle
Dissolution media	: Water
Media volume	: 900 mL
Rotation speed	: 100 rpm
Bath temperature	: 37 °C
Total time	: 240 min
Sampling time	: 5, 10, 20, 30, 50, 90, 180 and 240 min


Table 6 HPLC Conditions (α -Lipoic Acid)

Column	: Shim-pack VP-ODS ^{*1} (150 mm × 4.6 mm I.D., 5 μ m)
Mobile phase	: 10 mmol/L (Sodium) phosphate buffer (pH2.6) / acetonitrile = 30 : 70
Flow rate	: 1.0 mL/min
Column temp.	: 40 °C
Injection vol.	: 10 μ L
Vial	: Shimadzu Vial, LC, 1.1 mL, Glass ^{*2}
Detection	: UV 333 nm

*1 P/N: S228-41600-91 *2 P/N: 228-31537-91

Table 7 Reproducibility of Retention Time and Area for α -Lipoic Acid (100 mg/L, n=6)

	Retention time (min)	Area
1 st	2.368	39576
2 nd	2.370	39533
3 rd	2.369	39550
4 th	2.368	39719
5 th	2.368	39463
6 th	2.369	39566
Average	2.369	39568
%RSD	0.027	0.21



* Dissolution rate (%) = Concentration (mg/L) × Media volume 0.9 (L) / Labeled amount 105 (mg) × 100

Fig. 7 Dissolution Curve of α -Lipoic Acid

Table 8 Dissolution Rate of α -Lipoic Acid (%)

Vessel No.	Time (min)	5	10	20	30	50	90	180	240
1		24.3	40.6	54.9	65.3	75.5	88.1	91.7	91.9
2		26.2	48.8	63.2	69.3	74.8	85.0	91.9	92.1
3		24.0	47.9	63.0	69.9	74.3	81.4	89.1	90.1
4		16.6	33.4	52.0	62.1	74.6	83.4	87.8	88.6
5		18.8	34.7	56.3	64.4	71.8	84.3	89.4	89.3
6		18.8	34.7	56.3	64.4	71.8	84.3	89.4	89.3
Average		21.4	40.0	57.6	65.9	73.8	84.4	89.9	90.2
%RSD		16.5	15.8	7.2	4.3	2.0	2.4	1.6	1.5

Nexera, LabSolutions, and Shim-pack are trademarks of Shimadzu Corporation or its affiliated companies in Japan and/or other countries.



Shimadzu Corporation
Analytical & Measuring Instruments Division
Global Application Development Center

www.shimadzu.com/an/

For Research Use Only. Not for use in diagnostic procedures.

This publication may contain references to products that are not available in your country. Please contact us to check the availability of these products in your country. The content of this publication shall not be reproduced, altered or sold for any commercial purpose without the written approval of Shimadzu. See <http://www.shimadzu.com/about/trademarks/index.html> for details.

Third party trademarks and trade names may be used in this publication to refer to either the entities or their products/services, whether or not they are used with trademark symbol "TM" or "®".

The information contained herein is provided to you "as is" without warranty of any kind including without limitation warranties as to its accuracy or completeness. Shimadzu does not assume any responsibility or liability for any damage, whether direct or indirect, relating to the use of this publication. This publication is based upon the information available to Shimadzu on or before the date of publication, and subject to change without notice.

01-00031-EN

First Edition: Oct. 2021